- Nano cap InspireMD (NSPR +1.5%) is up on below-average volume in response to updated data on its CGuard Embolic Prevention System (EPS). The results were presented at the VEITHsymposium in New York.
- Results from a study in Poland involving 251 patients with high-risk stenosis (narrowing) in the carotid arteries (arteries located on each side of the neck that transport blood the head, brain and face) showed a treatment benefit and favorable safety profile at 36 months of follow-up.
- Six-month follow-up data on 70 patients in Germany showed a 100% technical success rate with no peri- or post-interventional strokes observed and no intra-stent restenosis (artery narrows again after the procedure).
- The company says CGuard EPS is designed to prevent embolization by trapping potential emboli (e.g., blood clot, air bubble, fatty deposit) against the arterial wall by virtue of its MicroNet technology.
- Previously: InspireMD's CGuard EPS shows sustained benefit in extension study; shares ahead 8% premarket (May 30)
- Now read: Tocagen teams up with NRG Oncology in study of Toca 511 & Toca FC in brain cancer
Original article